For each cement powder, the number-average molecular weight and weight-average molecular weight (and, hence, the polydispersity index, PDI) were determined using gel permeation chromatography For each of the cured cements, the fatigue lives

(N(f)) of specimens, at loads corresponding to stresses (S) of +/- 10.0 MPa, +/- 12.5 MPa, +/- 15.0 MPa, and +/- 20.0 MPa, were determined using the protocol detailed in ASTM F2118-03. Hence, the values of the three Weibull parameters were determined for each cement set-S combination. From these results, one index of the fatigue life of the cement, namely, the Weibull mean fatigue life (N(WM)), was computed for each combination. For Pexidartinib solubility dmso each cement, the Olgive equation was fitted to the S-N(f) results, yielding an estimate of another fatigue property, the cement’s fatigue limit. Best-fit empirical relationships (1) between In N(WM), AZD1480 supplier S, and PDI, and (2) between the estimated fatigue limit and

PDI were obtained. These relationships may be used in the development of new cement powder sterilization methods. (C) 2009 Elsevier Ltd. All rights reserved.”
“Background. We conducted this retrospective study to identify reasons that patients referred to a phase I clinical trial failed to enroll or delayed enrollment onto the trial. Materials and Methods. Outcome analyses were conducted independently on data collected from electronic medical records of two sets of consecutive patients referred to a phase I clinical trial facility at MD Anderson Cancer Center. Data from the first set of 300 patients were used to determine relevant variables affecting enrollment; data from the second set of

957 patients were then analyzed for these variables. Results. Results from the two sets of patients were similar. Approximately 55% of patients were enrolled PXD101 concentration in a phase I trial. Patients referred from within MD Anderson were more likely to be enrolled than patients seen originally outside the institution (p = .006); black patients were more likely than white patients to enroll (69% vs. 43%; p = .04). The median interval from the initial visit to initiation of treatments was 19 days. Major reasons for failure to enroll included failure to return to the clinic (36%), opting for treatment in another clinic (17%), hospice referral (11%), early death (10%), and lack of financial clearance (5%). Treatment was delayed for three weeks or more in 250 patients; in 85 patients (34%), the delay was caused by financial and insurance issues. Conclusion. Failure to return to the clinic, pursuit of other therapy, and rapid deterioration were the major reasons for failure to enroll; lengthy financial clearance was the most common reason for delayed enrollment onto a phase I trial.